Retina

EyePoint has finished enrolling both pivotal Phase 3 trials evaluating its sustained-release intravitreal insert against aflibercept in diabetic macular edema, setting up a topline readout in late 2027.

Patient enrollment is complete in a phase 3 registrational, or pivotal, trial to evaluate OPGx-LCA5, a gene therapy that is under investigation for treating Leber congenital amaurosis type 5-associated inherited retinal disease.

Margaret A. Chang, MD, MS, on MK-8748's dual Tie2/VEGF mechanism, what MALBEC's data must show to shift wet AMD care, and where DME and RVO fit next.

A maternal high-fat diet can negatively affect the retinal structure in mice.

Bakall on 3-year REMAIN data for MCO-010 in retinitis pigmentosa: durable 3-line acuity gains, why genotype did not matter, and which patients responded best.

An investigational treatment for vision loss associated with Bardet-Biedl syndrome is being tested in the first three patients treated.

Barakat, MD, FASRS, on recognizing neovascular conversion in macular telangiectasia type 2, distinguishing it from neovascular AMD on imaging, and treating it without a robust evidence base.

Wet AMD gains a new FDA-approved therapy as retina, glaucoma, and dry eye pipelines surge—plus AI, devices, and workforce trends reshaping care.

The FDA has cleared an IND for RAG-1C, a first-in-class saRNA therapy targeting proliferative vitreoretinopathy.

Steffen Schmitz-Valckenberg, MD, discusses how optical coherence tomography-based models may enable rapid, noninvasive assessment of functional loss in GA at Angiogenesis 2026.

Physician AI use has more than doubled since 2023—but the next leap in ophthalmology won't come from smarter diagnostic algorithms alone.

Why AI-driven functional imaging could change how clinicians assess and treat retinal disease

The approval establishes LYTENAVA as the first and only FDA-approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the United States.

Louie Cai, MD, discusses why manual prescreening is so labor-intensive, how the study was designed, and what broader adoption of AI-assisted screening could mean for clinician time, patient satisfaction, and the pace of drug development.

Danon disease is a rare, multisystem X-linked genetic disorder caused by variants in the LAMP2 gene. In children and young adults, it is defined overwhelmingly by its cardiac effects . What is far less appreciated is that the eye is frequently involved and that the retinal findings can appear before the systemic diagnosis is established.

Microsecond green laser (520 nm; Norlase) improved visual acuity and reduced macular thickness in eyes with chronic central serous chorioretinopathy (CSCR)

PRIMA, the first brain-computer interface approved for form vision restoration (reading letters, numbers, words) in patients with geographic atrophy (GA) secondary to age-related macular degeneration, is commercially available in Europe.

Real-world data presented at ASRS 2026 show pegcetacoplan slowed photoreceptor and RPE loss in geographic atrophy, with a greater treatment effect in eyes with concurrent neovascular AMD.

A wider partial-total ellipsoid zone gap on OCT predicted faster total EZ loss and geographic atrophy in intermediate AMD—pointing to a biomarker for trial enrichment.

Presenters highlight clinical insights and lessons from recent trial data and surgical experience

3-year REMAIN data show MCO-010 optogenetic therapy delivered durable ~3-line vision gains in retinitis pigmentosa regardless of gene mutation, with no treatment-related serious adverse events, per Benjamin Bakall, MD, PhD, at ASRS 2026.

ARCHER data reveal which GA eyes risk major vision loss: midrange baseline acuity and subfoveal lesions, shaping counseling and future AMD trials.

Inflammasome Therapeutics announced positive phase 2 results achieved by kamuvudine-8 (K8), its investigational drug, for geographic atrophy (GA) and a good safety signal over the 6-month period of evaluation. The company also reported significantly slower GA progression and a visual acuity advantage.

An AI platform that screens patient charts for clinical trial eligibility increased randomization by 37.5% and cut screen failures by 13% in a retina practice.

Arshad M. Khanani, MD, MA, discusses phase 3 SOL-1 data showing axitinib sustained vision in wet AMD for 9-12 months after 1 dose, outperforming aflibercept 2 mg.